Optimind Pharma

Optimind Pharma P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Optimind Pharma (OMND.CN) as of Nov 2, 2026 is 34.63. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -2.51 — a change of -1,478.15% (higher).

P/FCF

34.63

YoY

-1,478.15%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Optimind Pharma is 2026 34.63 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Optimind Pharma was 2025 -2.51 . It decreases by -1,478.15% higher compared to the previous year.

The Optimind Pharma P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-3.26 CAD
Jan 1, 2019
-10.23 CAD
Jan 1, 2020
-5.50 CAD
Jan 1, 2021
-5.80 CAD
Jan 1, 2023
-0.52 CAD
Jan 1, 2024
-1.15 CAD
Jan 1, 2025
-2.51 CAD
Jan 1, 2026
34.63 CAD
The Optimind Pharma P/FCF history
YEARP/FCFYoY
34.63-1,478.15%
-2.51+118.81%
-1.15+121.36%
-0.52-91.06%
-5.80+5.37%
-5.50-46.18%
-10.23+213.45%
-3.26-19.09%
-4.03-20.61%
-5.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Optimind Pharma Stock analysis

What does Optimind Pharma do? Optimind Pharma Corp. generates revenue through medical cannabis and ketamine-assisted treatments for mental health conditions including PTSD, anxiety, and depression. The company offers two treatment types: Monotherapy and assisted therapy, both utilizing ketamine capsules. These programs integrate psychedelic medicine with therapeutic processing, based on scientific research and established therapeutic modalities. The firm partners with psilocybin treatment developers to expand its offerings, targeting patients seeking alternative mental health solutions through psychedelic-enhanced psychotherapy. Optimind Pharma Corp.'s primary customers are individuals suffering from mental illnesses and disabilities, particularly those with PTSD, anxiety, and depression. The company's treatment programs are designed to restore cognitive function within two hours of ketamine capsule administration, appealing to patients seeking rapid therapeutic effects. By combining ketamine with therapeutic integration, the firm addresses a growing market demand for innovative mental health treatments beyond conventional pharmaceuticals. The company's revenue streams include direct patient treatment services and partnerships with psilocybin-associated treatment developers. These partnerships allow Optimind to offer expanded program options without developing new products internally. The focus on scientifically backed psychedelic-enhanced psychotherapy differentiates Optimind in the mental health treatment sector, targeting patients who prefer non-traditional approaches to managing mental health conditions. Optimind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Optimind Pharma stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Optimind Pharma is 34.63 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Optimind Pharma changed from -2.51 to 34.63, representing a -1,478.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Optimind Pharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Optimind Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Optimind Pharma

All Key Metrics — Optimind Pharma